Arrowhead Pharmaceuticals Presents Promising Clinical Data on ARO-RAGE for Asthma Treatment
Arrowhead Pharmaceuticals recently shared interim clinical data on their investigational RNAi-based medicine, ARO-RAGE, for the treatment of inflammatory lung diseases like asthma. The results, presented at the American Thoracic Society Conference, showed that ARO-RAGE effectively reduced the concentration of soluble RAGE (sRAGE) in bronchoalveolar lavage fluid. This data offers hope for a potential new therapy for asthma patients.
In addition to this development, Arrowhead Pharmaceuticals also announced plans to host a series of R&D webinars, showcasing their clinical candidates that utilize their proprietary Targeted RNAi Molecule platform. These webinars will focus on different therapeutic areas, allowing Arrowhead team members to present their findings and advancements in various fields.
Furthermore, Arrowhead Pharmaceuticals has begun a Phase 1/2a clinical trial for ARO-CFB, their investigational RNA interference therapeutic targeting complement-mediated kidney disease. The trial will involve up to 66 healthy volunteers and patients, and initial results have shown promising potential for this treatment.
In conclusion, Arrowhead Pharmaceuticals is making significant progress in the field of RNA-based therapeutics. The recent clinical data on ARO-RAGE for asthma treatment, along with their ongoing research in other therapeutic areas, demonstrates the company’s commitment to developing innovative solutions for various diseases.
Comments